metricas
covid
Annals of Hepatology P-53 IMMUNE-MEDIATED ADVERSE EVENTS FOLLOWING ATEZOLIZUMAB PLUS BEVACIZUMAB IS A...
Journal Information

Statistics

Follow this link to access the full text of the article

P-53 IMMUNE-MEDIATED ADVERSE EVENTS FOLLOWING ATEZOLIZUMAB PLUS BEVACIZUMAB IS ASSOCIATED WITH DECREASED SURVIVAL IN PATIENTS WITH CIRRHOSIS
FEDERICO PIÑERO1, Margarita Anders2, Carla Bermúdez3, Ezequiel Demirdjian4, Adriana Varón5, Daniela Perez6, Jorge Rodriguez7, Oscar Beltrán5, Javier Delgado García8, Leonardo Gomes da Fonseca9, Ezequiel Ridruejo10, Pablo Caballini11, Alexandre Araujo12, Juan Diego Torres Florez13, Juan Ignacio Marín14, Marina Villa15, Federico Orozco Ganem2, Jaime Poniachik8, Sebastián Marciano3, Fernando Bessone11..., Marcelo Silva1, Manuel Mendizabal1Ver más
1 HOSPITAL UNIVERSITARIO AUSTRAL, Pilar, Argentina
2 Hospital Alemán, Buenos Aires, Argentina
3 Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
4 Sanatorio Sagrado Corazón, Buenos Aires, Argentina
5 Fundación Cardioinfantil, Bogotá, Argentina
6 Hospital Padilla, Tucumán, Argentina
7 Hospital Central, Mendoza, Argentina
8 Hospital Clínico de la Universidad de Chile, Santiago, Chile
9 Instituto do Cancer do Estado de São Paulo, Hospital das Clínicas, Universidade São Paulo, Sao Paulo, Brasil
10 Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina
11 Hospital Centenario, Rosario, Argentina
12 Hospital das Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul., Porto Alegre, Brasil
13 Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia
14 Hospital Pablo Tobón Uribe, Medellín, Colombia
15 Hospital Comarcal de Blanes, Córdoba, Argentina
Ver más
Read
1149
Times
was read the article
198
Total PDF
951
Total HTML
Share statistics
Article information
ISSN: 16652681
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 12 14 4 18
2025 11 39 39 78
2025 10 27 30 57
2025 9 35 27 62
2025 8 504 19 523
2025 7 31 24 55
2025 6 32 8 40
2025 5 29 10 39
2025 4 22 7 29
2025 3 27 5 32
2025 2 50 4 54
2025 1 97 4 101
2024 12 44 17 61
Show all

Follow this link to access the full text of the article